2020
Management of vitreous floaters: an international survey the European VitreoRetinal Society Floaters study report
Zeydanli EO, Parolini B, Ozdek S, Bopp S, Adelman RA, Kuhn F, Gini G, Sallam AB, Aksakal N. Management of vitreous floaters: an international survey the European VitreoRetinal Society Floaters study report. Eye 2020, 34: 825-834. PMID: 32313173, PMCID: PMC7182575, DOI: 10.1038/s41433-020-0825-0.Peer-Reviewed Original ResearchMeSH KeywordsHumansPostoperative ComplicationsRetinal DetachmentRetinal PerforationsRetrospective StudiesVitrectomyVitreous BodyConceptsRelevant financial relationshipsFollowing relevant financial relationshipsRetrospective survey studyNovartis Pharmaceuticals CorporationAmerican Nurses Credentialing CenterSymptomatic floatersBoehringer Ingelheim PharmaceuticalsJournal CME author disclosure informationLaurie BarclayHeidelberg Pharma GmbHSpeakers bureauBayer AGAccreditation CouncilObjectivesUpon completionSurvey studySymptomatic improvementVitreous floatersSafety outcomesPatient careClinical implicationsHealthcare teamClinical researchAllerganMedscapePharmaceutical corporationsContinuing Medical Education
2019
Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern®. Ophthalmology 2019, 127: p145-p183. PMID: 31757497, DOI: 10.1016/j.ophtha.2019.09.022.Peer-Reviewed Original Research
2017
ASSOCIATION BETWEEN THE VITREOMACULAR INTERFACE AND OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS IN WET AGE-RELATED MACULAR DEGENERATION
Ashraf M, Souka A, Adelman RA. ASSOCIATION BETWEEN THE VITREOMACULAR INTERFACE AND OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS IN WET AGE-RELATED MACULAR DEGENERATION. Retina 2017, 37: 1738-1745. PMID: 28005632, DOI: 10.1097/iae.0000000000001423.Peer-Reviewed Original ResearchConceptsType 1 choroidal neovascularizationChoroidal thicknessChoroidal neovascularizationWet AMDVitreomacular adhesionDry AMDVitreomacular interfaceMacular degenerationRetrospective observational cross-sectional studyOptical coherence tomography examinationObservational cross-sectional studyAge-related macular degenerationType of CNVPaired-eye studyMean choroidal thicknessCross-sectional studySignificant differencesOptical coherence tomographyWet AgeSubgroup analysisTomography examinationHeidelberg SpectralisPatientsCoherence tomographyDegeneration characteristic
2015
Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern® Guidelines
Folk JC, Adelman RA, Flaxel CJ, Hyman L, Pulido JS, Olsen TW. Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern® Guidelines. Ophthalmology 2015, 123: p152-p181. PMID: 26578445, DOI: 10.1016/j.ophtha.2015.10.048.Peer-Reviewed Original ResearchMeSH KeywordsDisease ManagementEpiretinal MembraneHumansMacula LuteaOphthalmologyPractice Patterns, Physicians'Vitreous Body
2012
Microbial Spectrum and Resistance Patterns in Endophthalmitis: A 21-Year (1988–2008) Review in Northeast United States
Chen X, Adelman RA. Microbial Spectrum and Resistance Patterns in Endophthalmitis: A 21-Year (1988–2008) Review in Northeast United States. Journal Of Ocular Pharmacology And Therapeutics 2012, 28: 329-334. PMID: 22506856, DOI: 10.1089/jop.2011.0204.Peer-Reviewed Original ResearchEffects of Music Therapy on Intravitreal Injections: A Randomized Clinical Trial
Chen X, Seth RK, Rao VS, Huang JJ, Adelman RA. Effects of Music Therapy on Intravitreal Injections: A Randomized Clinical Trial. Journal Of Ocular Pharmacology And Therapeutics 2012, 28: 414-419. PMID: 22506884, DOI: 10.1089/jop.2011.0257.Peer-Reviewed Original ResearchConceptsMusic therapy groupIntravitreal injectionTherapy groupControl groupOutpatient settingClinical trialsMusic therapyFuture injectionsRandomized clinical trialsMain outcome measuresPost-procedure questionnaireSpielberger State-Trait Anxiety InventorySTAI-S scoresState-Trait Anxiety InventoryTrait Anxiety InventoryRetina clinicMost patientsPain QuestionnaireSafe interventionSubjective painOutcome measuresPatientsPainTherapyGreater decrease
2010
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman RA, Zheng Q, Mayer HR. Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal Of Ocular Pharmacology And Therapeutics 2010, 26: 105-110. PMID: 20187807, DOI: 10.1089/jop.2009.0076.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInjections, IntraocularIntraocular PressureMacular DegenerationMaleOcular HypertensionRanibizumabRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVitreous BodyConceptsAge-related macular degenerationPersistent ocular hypertensionOcular hypertensionIntraocular pressureIntravitreal bevacizumabRanibizumab injectionsIntravitreal injectionPrevious diagnosisGlaucoma/ocular hypertensionIntravitreal anti-VEGF injectionsAnti-VEGF injectionsIntravitreal bevacizumab injectionPostinjection intraocular pressurePreinjection intraocular pressureMultiple intravitreal injectionsTertiary referral centerRetrospective case seriesElevated intraocular pressureBevacizumab injectionIntravitreal ranibizumabReferral centerCase seriesVEGF injectionIOP increaseYAG capsulotomy
2009
ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
SETH RK, SALIM S, SHIELDS MB, ADELMAN RA. ASSESSMENT OF OPTIC NERVE CUP-TO-DISK RATIO CHANGES IN PATIENTS RECEIVING MULTIPLE INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS. Retina 2009, 29: 956-959. PMID: 19584654, DOI: 10.1097/iae.0b013e3181a91dfd.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideDrug Therapy, CombinationEyeFollow-Up StudiesFundus OculiHumansInjectionsIntraocular PressureOptic DiskOptic NerveRanibizumabRegional Blood FlowRetrospective StudiesSingle-Blind MethodVascular Endothelial Growth Factor AVitreous BodyConceptsMultiple intravitreal injectionsAnti-VEGF agentsIntraocular pressure riseIntraocular pressure fluctuationIntravitreal injectionMean changeControl groupTransient intraocular pressure riseSignificant differencesDisc ratio changesOptic nerve cupHistory of glaucomaAdditional prospective studiesGrowth factor effectsFellow eyesGlaucoma specialistsOptic nerveProspective studyOptic disc imagesFundus photographsTriamcinolone acetonideInclusion criteriaDisc ratioVertical cupPatientsA study of macular hole formation by serial spectral optical coherence tomography
Michalewska Z, Michalewski J, Sikorski BL, Kałużny J, Wojtkowski M, Adelman RA, Nawrocki J. A study of macular hole formation by serial spectral optical coherence tomography. Clinical And Experimental Ophthalmology 2009, 37: 373-383. PMID: 19594564, DOI: 10.1111/j.1442-9071.2009.02041.x.Peer-Reviewed Original Research
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator